Mitoxantrone Hydrochloride Liposome Injection

DRUG17 trials

Sponsors

CSPC ZhongQi Pharmaceutical Technology Co., Ltd., CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd., The First Hospital of Jilin University, Ming-Yuan Chen

Conditions

Advanced Pancreatic CancerAdvanced Recurrent or Metastatic Breast CancerAdvanced Solid TumorAdvanced Solid TumorsBreast CancerDiffuse Large B-Cell LymphomaDiffuse Large B-cell LymphomaNeuromyelitis Optica Spectrum Disorder

Phase 1

A Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Advanced Bone and Soft Tissue Sarcoma

TerminatedNCT04900766

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Unresectable or Metastatic Bone and Soft Tissue Sarcoma

Start: 2021-08-11End: 2023-02-03Updated: 2024-03-07

A Study of Mitoxantrone Hydrochloride Liposome Injection in Chinese Patients With Advanced Solid Tumors

CompletedNCT04921878

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Advanced Solid Tumors

Start: 2021-07-30End: 2023-04-03Updated: 2024-02-09

Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MM

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.Relapsed or Refractory Multiple Myeloma

Start: 2021-10-20End: 2024-06-20Target: 60Updated: 2022-02-01

A Study to Evaluate the Tolerance and Efficacy of Mitoxantrone Hydrochloride Liposome Injection Combined With Cytarabine in Patients With Acute Myeloid Leukemia (AML)

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Treatment-naive or Relapsed or Refractory Acute Myeloid Leukemia (AML)

Start: 2021-12-31End: 2023-06-30Target: 58Updated: 2021-10-29

Clinical Pharmacokinetics of Mitoxantrone Hydrochloride Liposome Injection in Recurrent/Refractory Lymphoma Subjects

CompletedNCT05173545

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Recurrent/Refractory Lymphoma

Start: 2019-07-29End: 2020-10-28Updated: 2021-12-30

A Study of Mitoxantrone Hydrochloride Liposome Injection Combination Therapy in Chinese Patients With Advanced Solid Tumors

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Advanced Solid Tumor

Start: 2022-04-30End: 2025-03-31Target: 116Updated: 2022-04-25

Phase 2

A Study of Mitoxantrone Hydrochloride Liposome Injection in Advanced Recurrent or Metastatic Breast Cancer

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Advanced Recurrent or Metastatic Breast Cancer

Start: 2015-06-30End: 2018-09-30Target: 60Updated: 2018-08-17

A Study of Liposome-entrapped Mitoxantrone Hydrochloride Injection in Relapsed/Refractory Peripheral T-cell Lymphoma and NK/T-cell Lymphoma

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Relapsed or Refractory Peripheral T-cell and NK/T-cell Lymphoma

Start: 2018-04-02End: 2020-12-30Target: 106Updated: 2018-12-14

A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced HER2 Negative Breast Cancer

TerminatedNCT04927481

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Breast Cancer

Start: 2021-06-11End: 2023-01-17Updated: 2024-02-23

A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced Pancreatic Cancer

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Advanced Pancreatic Cancer

Start: 2021-11-30End: 2024-05-31Target: 38Updated: 2021-10-29

A Study of Mitoxantrone Hydrochloride Liposome Injection for Relapsing Multiple Sclerosis

WithdrawnNCT05496894

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.Relapsing Multiple Sclerosis

Start: 2022-08-31End: 2022-11-08Updated: 2022-12-15

Efficacy and Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)

CompletedNCT05551598

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.Neuromyelitis Optica Spectrum Disorder

Start: 2022-11-28End: 2024-07-18Updated: 2024-08-07

Mitoxantrone Hydrochloride Liposome Injection in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Diffuse Large B-Cell Lymphoma

Start: 2023-07-10End: 2025-09-30Target: 104Updated: 2024-02-08

Clinical Study of Mitoxantrone Hydrochloride Liposome Combined with PD-1 Blockade in Recurrent or Metastatic NPC

RecruitingNCT06472713

Ming-Yuan ChenRecurrent or Metastatic Nasopharyngeal Carcinoma

Start: 2024-07-20End: 2027-09-30Target: 32Updated: 2025-01-13

Phase 3

Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL

Active, not recruitingNCT04668690

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Peripheral T Cell Lymphoma

Start: 2021-04-13End: 2028-12-30Updated: 2025-05-31

Clinical Study of Mitoxantrone Hydrochloride Liposome Injection Combined With Capecitabine Versus Capecitabine Monotherapy in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma Who Failed Platinum-containing Treatment

Not yet recruitingNCT05717764

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.Recurrent Metastatic Nasopharyngeal Carcinoma

Start: 2023-02-28End: 2027-09-30Target: 500Updated: 2023-02-08

Unknown Phase

The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission.

Not yet recruitingNCT05990985

The First Hospital of Jilin UniversityDiffuse Large B-cell Lymphoma

Start: 2023-09-01End: 2026-08-01Target: 20Updated: 2023-08-18

Related Papers

Liposomal mitoxantrone versus chidamide in relapsed/refractory peripheral T-cell lymphoma: Final analysis from the multicenter, prospective randomized phase 3 study

Blood2025-11-03

Bortezomib, Mitoxantrone Hydrochloride Liposome, and Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Multi‐Center, Open‐Label Phase I Trial

Cancer Medicine2025-04-01

Liposomal mitoxantrone monotherapy in patients with relapsed or refractory mature T‐cell and natural killer‐cell neoplasms: A phase 2, multicenter, open‐label, single‐arm trial

Cancer2025-01-015 citations

Efficacy and safety of mitoxantrone hydrochloride liposome injection in Chinese patients with advanced breast cancer: a randomized, open-label, active-controlled, single-center, phase II clinical trial

Investigational New Drugs2021-10-1132 citations

Safety and Efficacy of Mitoxantrone Hydrochloride Liposome in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma and Extranodal NK/T-Cell Lymphoma: A Prospective, Single-Arm, Open-Label, Multi-Center, Phase Ⅱ Clinical Trial

Blood2020-11-0413 citations

Efficacy and safety of liposomal mitoxantrone (Lipo-MIT) in advanced breast cancer (ABC): A randomized, open label, active-controlled, single-center, phase II clinical trial.

Journal of Clinical Oncology2020-05-202 citations

Safety and Efficacy of Mitoxantrone Hydrochloride Liposome in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma and Extranodal NK/T-Cell Lymphoma: A Multicenter, Single-Arm, Open-Label, Phase 2 Clinical Trial

Blood2019-11-133 citations